$PROF News

Wall Street Analysts See a 59.68% Upside in Profound Medical (PROF): Can the Stock Really Move This High?

Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026

Profound Medical Annual General and Special Meeting of Shareholders Voting Results

Profound Medical Corp. (PRN:CA) Shareholder/Analyst Call Prepared Remarks Transcript

Profound Medical (PROF) Reports Q1 Loss, Tops Revenue Estimates

Profound Medical Corp. (TSE:PRN) Is Expected To Breakeven In The Near Future

Profound Medical Showcases TULSA Data, AI Software Upgrades, and Reimbursement Tailwinds at Conference

CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence

Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24

Profound Medical shares are trading lower after the company reported worse-than-expected Q4 financial results.

Profound Medical shares are trading lower after the company reported worse-than-expected Q4 financial results.

Profound Medical Corp (PROF) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic ...

Profound Medical Corp. (PRN:CA) Q4 2025 Earnings Call Transcript

Profound Medical Q4 Earnings Assessment

Earnings Summary: Profound Medical Q4

Profound Medical Q4 EPS $(0.27) Misses $(0.26) Estimate, Sales $5.977M Miss $7.233M Estimate

Profound Medical's Earnings: A Preview

Profound Medical Announces First Prostate Cancer Patient Treated With TULSA-PRO At Mount Sinai Hospital

Watching Profound Medical; Hearing Zacks Under $10 Newsletter Mentions Stock As A Buy

Lake Street Maintains Buy on Profound Medical, Raises Price Target to $12